Cost-effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalemia in patients with chronic kidney disease or heart failure in Spain.
Chronic kidney disease
Ciclosilicato de sodio y zirconio
Cost-effectiveness
Coste-efectividad
Enfermedad renal crónica
Heart failure
Hiperpotasemia
Hyperkalemia
Insuficiencia cardíaca
Sodium zirconium cyclosilicate
Journal
Nefrologia
ISSN: 2013-2514
Titre abrégé: Nefrologia (Engl Ed)
Pays: Spain
ID NLM: 101778581
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
28
11
2023
accepted:
27
02
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
29
10
2024
Statut:
aheadofprint
Résumé
Hyperkalemia (HK) is an electrolyte disturbance in the concentration of potassium ions (K Two microsimulation models reflecting the natural history of CKD and HF were used. In both models, K SZC is a more effective option in both pathologies, with a difference in QALYs of 0.476 in CKD and 0.978 in HF compared to standard treatment, and it represents an incremental cost of € 3,616 and € 14,749, respectively, obtaining an incremental cost-utility ratio of € 7,605/QALY in CKD and € 15,078/QALY in HF. SZC is a cost-effective alternative for the treatment of HK in patients with CKD or HF, taking into account the reference efficiency values commonly used in Spain.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Hyperkalemia (HK) is an electrolyte disturbance in the concentration of potassium ions (K
MATERIALS AND METHODS
METHODS
Two microsimulation models reflecting the natural history of CKD and HF were used. In both models, K
RESULTS
RESULTS
SZC is a more effective option in both pathologies, with a difference in QALYs of 0.476 in CKD and 0.978 in HF compared to standard treatment, and it represents an incremental cost of € 3,616 and € 14,749, respectively, obtaining an incremental cost-utility ratio of € 7,605/QALY in CKD and € 15,078/QALY in HF.
CONCLUSIONS
CONCLUSIONS
SZC is a cost-effective alternative for the treatment of HK in patients with CKD or HF, taking into account the reference efficiency values commonly used in Spain.
Identifiants
pubmed: 39472184
pii: S2013-2514(24)00183-4
doi: 10.1016/j.nefroe.2024.10.001
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Published by Elsevier España, S.L.U.